Role of mast cells in fibrosis of classical Hodgkin lymphoma

The underlying mechanism of fibrosis in classical Hodgkin lymphoma (CHL) remains uncertain. This study aimed to investigate the association of fibrosis in the lymph nodes of patients with CHL through histological examination of the expression of cytokines associated with fibrosis and mast cell proliferation. Additionally, we sought to determine the degree of mast cell infiltration in a nodular sclerosis subtype of CHL (NSCHL) compared with that in non-NSCHL. We analyzed lymph nodes from 22 patients with CHL, of which eight were of the NSCHL and 14 of the non-NSCHL subtype, using immunohistochemical staining of forkhead box P3 (FOXP3), transforming growth factor (TGF)-β, interleukin (IL)-3, IL-13, and stem cell factor (SCF). Mast cells were positive for TGF-β and IL-13, and FOXP3-positive cells were negative for TGF-β. Only the expression of IL-13 in Hodgkin and Reed–Sternberg (HRS) cells was significantly more frequently observed in NSCHL than that in non-NSCHL (P = 0.0028) and was associated with a higher rate of fibrosis (P = 0.0097). The number of mast cells was significantly higher in NSCHL than that in non-NSCHL (P = 0.0001). A significantly positive correlation was observed between the rate of fibrosis and the number of mast cells (correlation coefficient, 0.8524; 95% CI, 0.6725–0.9372) (P <0.0001). The number of mast cells was significantly higher in the group with IL-13-positive HRS cells than that in the group with IL-13-negative HRS cells (P = 0.0157). Based on these findings, we hypothesize that IL-13 production by HRS cells may lead to fibrosis, and furthermore, promote mast cell proliferation and infiltration. This in turn might further produce the fibrotic cytokines IL-13 and TGF-β, resulting in fibrosis typical of NSCHL.

[1]  S. O’Reilly Role of interleukin‐13 in fibrosis, particularly systemic sclerosis , 2013, BioFactors.

[2]  K. O'Reilly,et al.  Fibrosis of the lung and other tissues: new concepts in pathogenesis and treatment. , 2001, Clinical immunology.

[3]  B. Gruber Mast cells in the pathogenesis of fibrosis , 2003, Current rheumatology reports.

[4]  K. Ohshima,et al.  Interleukin‐13 and interleukin‐13 receptor in Hodgkin's disease: possible autocrine mechanism and involvement in fibrosis , 2001, Histopathology.

[5]  G. Dranoff,et al.  Role for interleukin-3 in mast-cell and basophil development and in immunity to parasites , 1998, Nature.

[6]  P. Kamper,et al.  Tumour‐associated mast cells in classical Hodgkin's lymphoma: correlation with histological subtype, other tumour‐infiltrating inflammatory cell subsets and outcome , 2016, European journal of haematology.

[7]  P. Hart Regulation of the inflammatory response in asthma by mast cell products , 2001, Immunology and cell biology.

[8]  L. Gu,et al.  Transforming growth factor beta 1 messenger RNA in Reed-Sternberg cells in nodular sclerosing Hodgkin's disease. , 1995, Journal of clinical pathology.

[9]  G. Ling,et al.  Mast Cell Infiltration Is Involved in Renal Interstitial Fibrosis in a Rat Model of Protein-Overload Nephropathy , 2010, Kidney and Blood Pressure Research.

[10]  T. Williams,et al.  Mechanisms underlying the localisation of mast cells in tissues. , 2011, Trends in immunology.

[11]  T. Wynn Fibrotic disease and the T(H)1/T(H)2 paradigm. , 2004, Nature reviews. Immunology.

[12]  C. Brightling,et al.  Mast cells express IL‐13Rα1: IL‐13 promotes human lung mast cell proliferation and FcɛRI expression , 2006, Allergy.

[13]  A. Longatto-Filho,et al.  KIT activation in uterine cervix adenosquamous carcinomas by KIT/SCF autocrine/paracrine stimulation loops. , 2008, Gynecologic oncology.

[14]  J. Smith,et al.  Stem cell factor: laboratory and clinical aspects. , 2001, Blood reviews.

[15]  K. Takata,et al.  T helper 2 and regulatory T-cell cytokine production by mast cells: a key factor in the pathogenesis of IgG4-related disease , 2014, Modern Pathology.

[16]  P. Venge,et al.  Predictors of histology, tissue eosinophilia and mast cell infiltration in Hodgkin’s Lymphoma – a population‐based study , 2011, European journal of haematology.

[17]  T. Wynn Fibrotic disease and the TH1/TH2 paradigm , 2004, Nature Reviews Immunology.

[18]  J. Karbach,et al.  Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans , 2013, Proceedings of the National Academy of Sciences.

[19]  Fu-you Liu,et al.  Mast cell, a promising therapeutic target in tubulointerstitial fibrosis. , 2007, Medical hypotheses.

[20]  R. Küppers,et al.  Hodgkin lymphoma. , 2012, The Journal of clinical investigation.

[21]  C. Pucillo,et al.  Mast Cell: An Emerging Partner in Immune Interaction , 2012, Front. Immun..

[22]  F. Herrmann,et al.  Hodgkin's disease: a tumor with disturbed immunological pathways. , 1997, Immunology today.

[23]  H. Zhou,et al.  Transforming growth factor beta 1 plays an important role in inducing CD4+CD25+forhead box P3+ regulatory T cells by mast cells , 2010, Clinical and experimental immunology.

[24]  G. Nilsson,et al.  Stem cell factor is a chemotactic factor for human mast cells. , 1994, Journal of immunology.

[25]  G. Nilsson,et al.  Mast cell infiltration correlates with poor prognosis in Hodgkin's lymphoma , 2002, British journal of haematology.

[26]  A. Stenzl,et al.  Evaluation of the KIT/stem cell factor axis in renal tumours. , 2012, Anticancer research.

[27]  M. Wills-Karp,et al.  Interleukin‐13 in asthma pathogenesis , 2004, Immunological reviews.

[28]  H. Xiong,et al.  SCF-mediated mast cell infiltration and activation exacerbate the inflammation and immunosuppression in tumor microenvironment. , 2008, Blood.

[29]  Hiroki Takahashi,et al.  The stem cell factor/c-kit receptor pathway enhances proliferation and invasion of pancreatic cancer cells , 2006, Molecular Cancer.

[30]  Z. Nemes,et al.  Retrospective analysis of the prognostic role of tissue eosinophil and mast cells in Hodgkin’s lymphoma , 2008, Pathology & Oncology Research.

[31]  T. Mak,et al.  The role of cytokines in classical Hodgkin lymphoma. , 2002, Blood.

[32]  A. Caraffa,et al.  Interrelationship between IL-3 and mast cells. , 2014, Journal of biological regulators and homeostatic agents.

[33]  A. Demircan,et al.  The prognostic relevance of angiogenesis and mast cells in squamous cell carcinoma of the oesophagus. , 2001, Journal of clinical pathology.

[34]  水野 紘樹 Mast cells promote the growth of Hodgkin's lymphoma cell tumor by modifying the tumor microenvironment that can be perturbed by bortezomib , 2013 .

[35]  Johan Lennartsson,et al.  Stem cell factor receptor/c-Kit: from basic science to clinical implications. , 2012, Physiological reviews.

[36]  G. Krystal,et al.  Autocrine growth of small cell lung cancer mediated by coexpression of c-kit and stem cell factor. , 1996, Cancer research.

[37]  B. Agnarsson,et al.  Immunohistochemical evidence of a role for transforming growth factor beta in the pathogenesis of nodular sclerosing Hodgkin's disease. , 1990, The American journal of pathology.